Characterization of Cardiac-Onset Initial Presentation in Friedreich Ataxia.
Cardiomyopathy
Hypertrophy
Mitochondria
Omaveloxolone
Journal
Pediatric cardiology
ISSN: 1432-1971
Titre abrégé: Pediatr Cardiol
Pays: United States
ID NLM: 8003849
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
26
11
2023
accepted:
23
01
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
We examined the clinical features of Friedreich ataxia (FRDA) patients who present first with cardiac disease in order to understand the earliest features of the diagnostic journey in FRDA. We identified a group of subjects in the FACOMS natural history study whose first identified clinical feature was cardiac. Only 0.5% of the total cohort belonged to this group, which was younger on average at the time of presentation. Their cardiac symptoms ranged from asymptomatic features to heart failure with severe systolic dysfunction. Two of those individuals with severe dysfunction proceeded to heart transplantation, but others spontaneously recovered. In most cases, diagnosis of FRDA was not made until well after cardiac presentation. The present study shows that some FRDA patients present based on cardiac features, suggesting that earlier identification of FRDA might occur through enhancing awareness of FRDA among pediatric cardiologists who see such patients. This is important in the context of newly identified therapies for FRDA.
Identifiants
pubmed: 38427090
doi: 10.1007/s00246-024-03429-5
pii: 10.1007/s00246-024-03429-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bidichandani SI, Delatycki MB. Friedreich Ataxia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2023 Nov 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1281/
Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254):1423–1427
doi: 10.1126/science.271.5254.1423
pubmed: 8596916
Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S et al (1997) Frataxin is reduced in friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6(11):1771–1780
doi: 10.1093/hmg/6.11.1771
pubmed: 9302253
Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC et al (2021) Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol 89(2):212–225
doi: 10.1002/ana.25934
pubmed: 33068037
The FA Clinical Outcome Measures Study (FA-COMS) - ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03090789
R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria; 2023. Available from: https://www.R-project.org/
McCormick A, Shinnick J, Schadt K, Rodriguez R, Addonizio L, Hirano M et al (2017) Cardiac transplantation in Friedreich ataxia: extended follow-up. J Neurol Sci 15(375):471–473
doi: 10.1016/j.jns.2017.01.027
Norrish G, Rance T, Montanes E, Field E, Brown E, Bhole V et al (2021) Friedreich’s ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. Arch Dis Child 2021:322455
Leonard H, Forsyth R (2001) Friedreich’s ataxia presenting after cardiac transplantation. Arch Dis Child 84(2):167–168
doi: 10.1136/adc.84.2.167
pubmed: 11159298
pmcid: 1718633
Rummey C, Corben LA, Delatycki M, Wilmot G, Subramony SH, Corti M et al (2022) Natural history of Friedreich ataxia: heterogeneity of neurologic progression and consequences for clinical trial design. Neurology 99(14):e1499–e1510
doi: 10.1212/WNL.0000000000200913
pubmed: 35817567
pmcid: 9576299
Koeppen AH (2011) Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 303(1–2):1–12
doi: 10.1016/j.jns.2011.01.010
pubmed: 21315377
pmcid: 3062632
Tadros HJ, Miyake CY, Kearney DL, Kim JJ, Denfield SW (2023) The many faces of arrhythmogenic cardiomyopathy: an overview. Appl Clin Genet 16:181–203
doi: 10.2147/TACG.S383446
pubmed: 37933265
pmcid: 10625769
Lees JG, Napierala M, Pébay A, Dottori M, Lim SY (2022) Cellular pathophysiology of Friedreich’s ataxia cardiomyopathy. Int J Cardiol. 346:71–78
doi: 10.1016/j.ijcard.2021.11.033
pubmed: 34798207
Koeppen AH, Ramirez RL, Becker AB, Bjork ST, Levi S, Santambrogio P et al (2015) The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One. 10(3):e0116396
doi: 10.1371/journal.pone.0116396
pubmed: 25738292
pmcid: 4349588
Friedman LS, Schadt KA, Regner SR, Mark GE, Lin KY, Sciascia T et al (2013) Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich ataxia. Int J Cardiol 167(4):1622–1624
doi: 10.1016/j.ijcard.2012.04.159
pubmed: 22633670
Takazaki KAG, Quinaglia T, Venancio TD, Martinez ARM, Shah RV, Neilan TG et al (2021) Pre-clinical left ventricular myocardial remodeling in patients with Friedreich’s ataxia: a cardiac MRI study. PLoS One. 16(3):e0246633
doi: 10.1371/journal.pone.0246633
pubmed: 33770103
pmcid: 7996973
Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP et al (2022) Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation 146(15):1123–1134
doi: 10.1161/CIRCULATIONAHA.121.058457
pubmed: 36154167
pmcid: 9555763
Weidemann F, Störk S, Liu D, Hu K, Herrmann S, Ertl G et al (2013) Cardiomyopathy of Friedreich Ataxia. J Neurochem 126:88–93
doi: 10.1111/jnc.12217
pubmed: 23859344
Del Franco A, Menale S, Chiti C, Biagioni G, Tomberli A, Zampieri M et al (2023) The evolving paradigm and current perception of hypertrophic cardiomyopathy: implications for management. Prog Cardiovasc Dis 80:8–13
doi: 10.1016/j.pcad.2023.08.002
pubmed: 37572782